Select связанные

Please select the category: Acquired Haemophilia A Acquired VWD Afibrinogenemia Alpha 2 antiplasmin deficiency Bernard-Soulier syndrome Combined FII, VII, IX, X deficiency Combined FV+VIII deficiency Dysfibrinogenemia Factor II deficiency Factor V deficiency Factor VII deficiency Factor X deficiency Factor XI deficiency Factor XIII deficiency Glanzmanns thrombasthenia Haemophilia A Haemophilia B Hypofibrinogenemia Inherited Bleeding Disorder Platelet storage pool disease Von Willebrand Disease

http://www.clinicaltrials.gov/ct2/results/rss.xml?&term=Inherited+Bleeding+Disorder&recr=Open&show_rss=Y&count=10000 Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
Condition:   Haemophilia
Interventions:   Diagnostic Test: Thrombophilia screen;   Diagnostic Test: Initiation pathway analysis
Sponsor: связанные   Royal Free Hospital NHS Foundation Trust
Not yet recruiting Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
Condition:   Hemophilia A
Intervention:   Biological: valoctocogene roxaparvovec
Sponsor:   BioMarin Pharmaceutical
Recruiting A Factor IX Gene Therapy Study (FIX-GT)
Condition:   Hemophilia B
Intervention:   Biological: FLT180a
Sponsor:   University College, London
Not yet recruiting Joint Health Study
Condition:   Hemophilia B
Intervention:  
Sponsors:   Bloodworks (Puget Sound Blood Center);   CSL Behring
Recruiting World Bleeding Disorders Registry
Conditions:   Hemophilia A;   Hemophilia B
Intervention:  
Sponsor:   World Federation of Hemophilia
Not yet recruiting Differences in Preparation for Small Bowel Capsule Endoscopy
Conditions:   Capsule Endoscopy;   Inflammatory Bowel Diseases;   Celiac Disease
Interventions:   Drug: Klean Prep;   Other: Clear liquids only
Sponsors:   Sheffield Teaching Hospitals NHS Foundation Trust;   Hotel Dieu Hospital
Not yet recruiting Comparison of Ideal vs. Actual Weight Base Factor Dosing
Condition:   Hemophilia A
Interventions:   Other: Ideal Body Weight First;   Other: Actual Body Weight First
Sponsors:   Bloodworks (Puget Sound Blood Center);   Seattle Children's Hospital;   Oregon Health and Science University;   Providence Health & Services
Recruiting Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
Condition:   Hemophilia A
Intervention:   Drug: Emicizumab
Sponsor:   Hoffmann-La Roche
Not yet recruiting Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia
Condition:   Severe Haemophilia
Intervention:  
Sponsor:   Assistance Publique Hopitaux De Marseille
Not yet recruiting Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
Conditions:   Haemophilia A;   Haemophilia B
Intervention:  
Sponsor:   Swedish Orphan Biovitrum
Not yet recruiting BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
Condition:   Hemorrhagic Hereditary Telangiectasia (HHT)
Interventions:   Drug: Bevacizumab;   Drug: sodium chloride 0.9%
Sponsor:   Hospices Civils de Lyon
Recruiting A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Conditions:   Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions:   Drug: Concizumab;   Drug: Eptacog alfa
Sponsor:   Novo Nordisk A/S
Recruiting HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound
Condition:   Moderate and Severe Haemophilia
Intervention:   Other: HEAD-US scoring system
Sponsors:   Guy's and St Thomas' NHS Foundation Trust;   Pfizer
Not yet recruiting Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa
Sponsor:   Novo Nordisk A/S
Not yet recruiting Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
Condition:   Factor 10 Deficiency
Intervention:   Drug: Coagadex
Sponsor:   Bio Products Laboratory
Not yet recruiting Factor XIII in Major Burns Coagulation
Conditions:   Burns;   Coagulation Disorder;   Factor XIII Deficiency;   Cicatrization;   Endothelial Dysfunction
Intervention:   Diagnostic Test: Coagulation tests
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting Low Von Willebrand in Ireland Cohort Study
Condition:   Von Willebrand Factor, Deficiency
Intervention:  
Sponsor:   St. James's Hospital, Ireland
Recruiting Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies
Condition:   Hemophilia
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Recruiting China Registry for Genetic / Metabolic Liver Diseases
Condition:   Genetic/Metabolic Liver Diseases
Intervention:   Drug: Standard of care
Sponsors:   Beijing Friendship Hospital;   Beijing YouAn Hospital;   Henan Provincial Hospital;   Beijing Ditan Hospital;   Hebei Medical University Third Hospital;   Peking University First Hospital;   Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital;   Nanfang Hospital of Southern Medical University;   Affiliated Hospital, Logistics University of People's Armed Police Force;   Beijing Anzhen Hospital, Capital Medical University;   West China Second University Hospital of Sichuan University;   Jinshan Hospital of Fudan University;   Fudan University
Recruiting Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
Condition:   Factor VII Deficiency
Interventions:   Biological: Eptacog alfa, biosimilar and reference medicinal product Novoseven;   Biological: Eptacog alfa biosimilar
Sponsor:   AryoGen Pharmed Co.
Recruiting A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Condition:   Hemophilia A With Inhibitors
Intervention:   Biological: rFVIIIFc
Sponsors:   Bioverativ Therapeutics Inc.;   Swedish Orphan Biovitrum
Recruiting Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Condition:   Antithrombin Deficiency Type 2
Intervention:   Drug: ATryn continuous infusion
Sponsors:   Mayo Clinic;   rEVO Biologics
Not yet recruiting Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
Condition:   Von Willebrand Diseases
Intervention:  
Sponsor:   University Hospital, Lille
Not yet recruiting UK - EHL Outcomes Registry
Conditions:   Hemophilia A;   Hemophilia B
Intervention:  
Sponsor:   Royal Free Hospital NHS Foundation Trust
Recruiting A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Conditions:   Haemophilia A;   Haemophilia B
Interventions:   Drug: ELOCTA;   Drug: ALPROLIX
Sponsor:   Swedish Orphan Biovitrum
Recruiting A Gene Transfer Study for Hemophilia A
Condition:   Hemophilia A
Intervention:   Genetic: SPK-8011
Sponsor:   Spark Therapeutics
Recruiting Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa pegol
Sponsor:   Novo Nordisk A/S
Recruiting MRA With Feraheme in HHT
Condition:   Hereditary Hemorrhagic Telangiectasia
Intervention:   Procedure: Feraheme MRI/MRA
Sponsor:   University of California, Los Angeles
Recruiting Immunmodulation in Patients With HHT
Condition:   Hereditary Haemorrhagic Telangiectasia (HHT)
Intervention:   Other: blood sample
Sponsor:   University Hospital, Essen
Recruiting Fascial Therapy in Elbow Hemophilic Arthropathy
Condition:   Hemophilia
Intervention:   Other: Experimental group
Sponsor:   Real Fundación Victoria Eugenia
Recruiting Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Interventions:   Drug: Mupirocin;   Other: Placebo
Sponsor:   Hospital Italiano de Buenos Aires
Not yet recruiting A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children
Condition:   Haemophilia
Intervention:   Other: Observe the patient's condition and then change the regimen
Sponsor:   Beijing Children's Hospital
Recruiting Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
Condition:   Hemophilia A
Interventions:   Drug: efmoroctocog alfa;   Drug: Factor VIII
Sponsor:   Swedish Orphan Biovitrum
Recruiting Graded TTCE for Post-Embolization PAVM Monitoring
Condition:   Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention:   Other: Transthoracic Contrast Echocardiogram
Sponsor:   University of Pennsylvania
Recruiting BAX 111 rVWF in Pediatrics
Condition:   Von Willebrand Disease
Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
Sponsor:   Baxalta now part of Shire
Not yet recruiting Low VW Activity in Adolescent HMB
Condition:   Von Willebrand Factor Deficiency
Interventions:   Other: Genetic Analysis;   Other: Medical Record Data Abstraction;   Other: Pictorial Blood Assessment Chart (PBAC) score;   Other: Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Shire
Recruiting rVWF IN PROPHYLAXIS
Condition:   Von Willebrand Disease
Interventions:   Biological: von Willebrand factor (Recombinant);   Biological: Antihemophilic Factor (Recombinant)
Sponsor:   Baxalta now part of Shire
Not yet recruiting Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
Condition:   Von Willebrand Disease
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Not yet recruiting Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
Condition:   Hemophilia A
Interventions:   Drug: Recombinant Factor VIII (50 IU/kg);   Drug: Recombinant Factor VIII (On-demand treatment)
Sponsor:   Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting BAX 802 in CHA With Inhibitors
Condition:   Hemophilia A
Intervention:   Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)
Sponsor:   Baxalta now part of Shire
Recruiting Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
Conditions:   Hereditary Hemorrhagic Telangiectasia;   Gastrointestinal Hemorrhage;   Anemia
Intervention:   Drug: Octreotide LAR
Sponsors:   Radboud University;   St. Antonius Hospital
Recruiting The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children
Conditions:   Benign Hypermobility Syndrome;   Functional Constipation
Intervention:  
Sponsor:   Medical University of Warsaw
Recruiting Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
Conditions:   Hypofibrinogenemia;   Afibrinogenemia;   Bleeding Disorders
Interventions:   Drug: RiaStAP;   Drug: Saline
Sponsor:   Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Recruiting Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia
Condition:   Haemophilia
Intervention:   Other: Patient questionnaire
Sponsor:   Assistance Publique Hopitaux De Marseille
Recruiting Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Condition:   Hemophilia A, Congenital
Intervention:   Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Sponsor:   Bayer
Recruiting TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia
Condition:   Haemophilia A
Intervention:   Other: Thrombin generation measurement.
Sponsor:   Hospices Civils de Lyon
Recruiting Investigation of the Genetics of Hematologic Diseases
Conditions:   Bone Marrow Failure Syndromes;   Erythrocyte Disorder;   Leukocyte Disorder;   Hemostasis;   Blood Coagulation Disorder;   Sickle Cell Disease;   Dyskeratosis Congenita;   Diamond-Blackfan Anemia;   Congenital Thrombocytopenia;   Severe Congenital Neutropenia;   Fanconi Anemia
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   Boston Children’s Hospital;   Baylor College of Medicine;   University of Memphis
Recruiting Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
Conditions:   Hemophilia A;   Factor VIII
Intervention:   Drug: Recombinant VIII factor
Sponsor:   Hospital Universitario La Fe
Recruiting Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Conditions:   Hereditary Hemorrhagic Telangiectasia (HHT);   Epistaxis
Interventions:   Drug: Floseal;   Other: Packing
Sponsors:   St. Michael's Hospital, Toronto;   The Ottawa Hospital
Recruiting Ultrasonography in Hemophilic Joint Disease and Serum Markers
Conditions:   Hemophilia A;   Hemophilia B;   Hemarthroses
Intervention:   Other: ultrasound
Sponsors:   Northwell Health;   National Cancer Institute (NCI);   University of California, San Diego
Recruiting Weight-based Dosing in Hemophilia A
Condition:   Hemophilia
Intervention:   Drug: rFVIII
Sponsor:   University of Pittsburgh
Recruiting Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition:   Acquired Hemophilia A
Intervention:   Biological: OBIZUR
Sponsor:   Baxalta now part of Shire
Recruiting Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease
Condition:   Type 1 Von Willebrand Disease
Interventions:   Drug: recombinant von Willebrand factor;   Drug: tranexamic acid
Sponsors:   Margaret Ragni;   University of North Carolina;   Carnegie Mellon University;   Duke University
Not yet recruiting Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)
Condition:   Von Willebrands Disease
Intervention:  
Sponsors:   Jonathan Roberts;   Blood Center of Wisconsin
Recruiting ATHN 2: Factor Switching Study
Condition:   Hemophilia
Interventions:   Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013;   Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Sponsors:   American Thrombosis and Hemostasis Network;   Shire;   CSL Behring;   Bioverativ Therapeutics Inc.
Recruiting Swiss Hemophilia Registry
Condition:   Hemophilia and Other Severe Bleeding Disorders
Intervention:   Other: Registry
Sponsor:   Swiss Hemophilia Network
Recruiting Study of Voncento® in Subjects With Von Willebrand Disease
Condition:   Von Willebrand Disease
Intervention:   Biological: Voncento
Sponsor:   CSL Behring
Recruiting Natural History Study of Factor IX Treatment and Complications
Condition:   Factor IX Deficiency
Intervention:   Other: Standard care with blood and urine sample collection
Sponsors:   Skane University Hospital;   Indiana Hemophilia and Thrombosis Center;   University of Bonn;   Biogen;   Swedish Orphan Biovitrum
Recruiting A Gene Therapy Study for Hemophilia B
Condition:   Hemophilia B
Intervention:   Genetic: SPK-9001
Sponsors:   Spark Therapeutics;   Pfizer
Recruiting Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Condition:   Hemophilia
Intervention:  
Sponsor:   Karolinska Institutet
Recruiting Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
Conditions:   Pulmonary Arteriovenous Malformations;   Hereditary Hemorrhagic Telangiectasia;   Asthma;   COPD
Intervention:   Other: Cardiopulmonary exercise test
Sponsor:   Imperial College London
Not yet recruiting Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Condition:   Von Willebrand Disease
Intervention:   Drug: plasma-derived FVIII/VWF concentrate Fanhdi
Sponsor:   Instituto Grifols, S.A.
Recruiting A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
Conditions:   Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Intervention:   Biological: Coagulation FVIIa (Recombinant)
Sponsors:   LFB USA, Inc.;   Laboratoire français de Fractionnement et de Biotechnologies
Recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions:   Hemophilia A;   Hemophilia B
Intervention:   Drug: MOD-5014
Sponsor:   Opko Biologics
Recruiting Intranasal Bevacizumab for HHT-Related Epistaxis
Conditions:   HHT;   Hereditary Hemorrhagic Telangiectasia;   Epistaxis;   Nose Bleeds;   Nasal Bleeding
Interventions:   Drug: Bevacizumab;   Drug: Placebo (Saline)
Sponsor:   Stanford University
Recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition:   Hemophilia A
Intervention:   Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Sponsor:   Bayer
Recruiting Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
Condition:   Congenital Fibrinogen Deficiency
Intervention:   Drug: Octafibrin
Sponsor:   Octapharma
Recruiting To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa
Sponsor:   Novo Nordisk A/S
Recruiting Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder
Condition:   Inherited Platelet Disorders
Intervention:   Other: Blood collection for platelet protein samples
Sponsors:   Hadassah Medical Organization;   Hebrew University of Jerusalem
Not yet recruiting Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Conditions:   Congenital Bleeding Disorder;   Haemophilia B
Intervention:   Drug: nonacog beta pegol
Sponsor:   Novo Nordisk A/S
Recruiting An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions:   Hemophilia A;   Severe Hemophilia A
Intervention:   Biological: rVIII‑SingleChain
Sponsor:   CSL Behring
Recruiting Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Conditions:   Hemophilia A;   Hemophilia B;   Von Willebrand's Disease
Intervention:  
Sponsors:   Karolinska University Hospital;   The Swedish Society of Medicine;   Karolinska Institutet
Recruiting ADVATE Hemophilia A Outcome Database (AHEAD)
Condition:   Hemophilia A
Intervention:   Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Sponsor:   Baxalta now part of Shire
Recruiting A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Condition:   Hemophilia B
Intervention:   Biological: rIX-FP
Sponsor:   CSL Behring
Recruiting Willebrand International Non-interventional Global Surveillance
Condition:   Von Willebrand Disease
Intervention:  
Sponsor:   Laboratoire français de Fractionnement et de Biotechnologies
Recruiting Modifiers of Disease Severity in Cerebral Cavernous Malformations
Conditions:   Cavernous Angioma, Familial;   Cerebral Cavernous Malformations;   Cerebral Cavernous Hemangioma
Intervention:  
Sponsors:   University of New Mexico;   University of California, San Francisco;   Barrow Neurological Institute;   Angioma Alliance;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Condition:   Hereditary Hemorrhagic Telangiectasia
Interventions:   Drug: Topical timolol maleate;   Drug: placebo saline drops
Sponsors:   St. Michael's Hospital, Toronto;   University of California, San Francisco;   The Hospital for Sick Children;   University of Toronto;   Sunnybrook Health Sciences Centre;   Ryerson University;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa pegol
Sponsor:   Novo Nordisk A/S
Recruiting Thrombocytopathy in Gaucher Disease Patients
Conditions:   Gaucher Disease;   Thrombocytopathy
Intervention:  
Sponsors:   Rabin Medical Center;   Genzyme, a Sanofi Company
Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Conditions:   Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome
Intervention:   Other: Observation
Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   Mach-Gaensslen Foundation Switzerland;   Baxalta Innovations GmbH, Wien, Austria
Recruiting Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Condition:   Hereditary Hemorrhagic Telangiectasia
Intervention:  
Sponsors:   St. Michael's Hospital, Toronto;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting Registry for Vascular Anomalies Associated With Coagulopathy
Conditions:   Multifocal Lymphangioendotheliomatosis With Thrombocytopenia;   Cutaneovisceral Angiomatosis With Thrombocytopenia;   Vascular Anomaly With Thrombocytopenia;   Hemangiomas
Intervention:   Other: no intervention
Sponsor:   Medical College of Wisconsin
Recruiting Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
Condition:   Von Willebrand Disease
Intervention:   Biological: Alphanate SD/HT
Sponsor:   Grifols Biologicals Inc.
Recruiting Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.
Condition:   Antithrombin III Deficiency
Intervention:   Drug: Plasma-derived AT-III concentrate
Sponsor:   Grifols Biologicals Inc.
Recruiting The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Condition:   Glanzmann Thrombasthenia
Intervention:  
Sponsors:   Rockefeller University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Conditions:   Blood Coagulation Disorders, Inherited;   Thrombotic Disorder
Intervention:  
Sponsor:   The University of Texas Health Science Center, Houston
Recruiting Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Condition:   Telangiectasia, Hereditary Hemorrhagic
Intervention:  
Sponsors:   Imperial College London;   British Heart Foundation
Recruiting Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Condition:   Telangiectasia, Hereditary Hemorrhagic
Intervention:  
Sponsors:   Imperial College London;   The Margaret Hayton HHT Fund
Recruiting Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Conditions:   Albinism;   Intestinal Disease;   Kidney Disease;   Myocardial Disease;   Pulmonary Fibrosis
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting
Источник: http://www.haemophiliacentral.org/ClinicalTrials.aspx


Поделись с друзьями



Рекомендуем посмотреть ещё:


Закрыть ... [X]

Cached Шапочка с косами поперечное вязание


Select связанные Select связанные Select связанные Select связанные Select связанные Select связанные Select связанные Select связанные Select связанные


ШОКИРУЮЩИЕ НОВОСТИ